Why is Moderna stock down 6.6% today?

Traders Union
All News
Stocks
Moderna slides 6.62% today to $190

Highlights

Moderna reported positive Phase 3 results for its personalized cancer vaccine candidate in combination with Keytruda for melanoma.
Analysts downgraded Moderna stock to Sell, citing ongoing net losses, negative cash flow, and continuing mRNA patent lawsuits.
Despite recent losses, shares of Moderna remain in a bullish trend with overbought indicators and an expected five-session range of $176.24 to $210.17.

Valuation doubts intensify as legal risks and executive changes emerge

Moderna recently reported positive Phase 3 trial results for its personalized cancer vaccine candidate, intismeran autogene, in combination with Merck's Keytruda for melanoma patients. The company was downgraded to Sell by several analysts due to concerns that its market valuation exceeds current and projected fundamentals. Moderna has reported significant net losses and negative cash flow in recent quarters, and legal risks persist following a federal judge's decision to allow ongoing patent infringement lawsuits related to its mRNA technology. A new Chief Operating Officer position was also announced to support the company's expansion into oncology.

Anton Kharitonov, expert at Traders Union, views Moderna's recent drop as a technical correction fueled by profit-taking and overextended buying. He notes negative cash flow and ongoing legal battles raise caution for long-term investors. Technical indicators remain bullish, but the overbought readings and downgrades from analysts signal high risk of further downside. Kharitonov warns that current valuations are difficult to justify given persistent losses and legal pressures. He concludes, "Traders should be defensive here, as the technical overbought zone and weak fundamentals expose MRNA to a deeper retracement if momentum falters."

Viktoras Karapetjanc, expert at Traders Union, highlights the resilience of Moderna's bullish price structure despite recent volatility. He believes the positive oncology developments and new executive hire position the company for future growth. Karapetjanc sees institutional interest remaining strong as long as technical momentum persists. He expects price consolidation to offer renewed entry opportunities, with the upside targeting $210.17 if resistance breaks. He states, "Further growth is expected in MRNA, as the bullish structure remains intact and positive sector news fuels confidence."

Sholanke Dele, market strategist, sees sentiment turning sharply negative after analyst downgrades despite strong trial results. He points out the market is reacting to skepticism over valuations and unresolved legal risks. Dele warns that elevated volatility and profit-taking signal fading investor confidence for now. He stresses that caution is warranted until the stock stabilizes above key support. He adds, "Investors should question the sustainability of recent rallies, given unresolved fundamental risks in MRNA."

Bullish trend dominates despite overbought signals and profit-taking surge

MRNA is trading above the 20-day, 50-day, and 200-day moving averages ($161.83, $115.72, $65.98), indicating strong bullish trends on short, medium, and long-term timeframes. The nearest support sits at the week low of $180.6, while resistance is marked at the intraday low of $196.66. The bullish alignment of the 50-day and 200-day moving averages confirms a robust long-term structure. Momentum signals are deeply bullish, with both MACD and ADX forecasting a buy. However, the RSI, Stochastic RSI, and CCI are all in overbought territory, and Bull/Bear Power is strongly positive at 32.25, highlighting dominant buyer interest and an overbought market. The Awesome Oscillator continues to support the ongoing bullish trend. Intraday trading shows sellers in control after the open, with the price near the intraday low and volatility elevated at 5.83%, suggesting increased profit-taking after the previous upward surge.

Earlier, analysts noted that Moderna's strong rally had left its valuation potentially vulnerable to a correction in the absence of fresh supporting data. The latest analyst downgrades and sharp pullback underscore that, despite strong momentum signals, the next pivotal level for traders is a sustained break of support at $176.24, which may trigger a deeper retracement.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.